Other armored CARs in development include an IL-18-secreting CD19 or MUC16 CAR, which appears to modulate the tumor microenvironment of both hematologic malignancies and solid tumors and helps enhance endogenous anti-tumor T cell responses (41). Here, MUC16 is linked to neoplasm.